Results 181 to 190 of about 43,320 (312)

Paeoniflorin, a Major Constituent of Peony Root, Reverses Muscarinic M1-Receptor Antagonist-Induced Suppression of Long-Term Potentiation in the Rat Hippocampal Slice.

, 2000
Keiichi Tabata, Kinzo Matsumoto, Hiroshi Watanabe   +2 more
openalex   +1 more source

Pharmacotherapeutic Controversies During Temperature Control After Out‐of‐Hospital Cardiac Arrest: A Semi‐Structured Literature Review

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 1, January 2026.
ABSTRACT Post‐resuscitation cardiac arrest care begins at the time of hospital admission and focuses on preventing the sequelae of ischemia–reperfusion injury, including secondary brain damage and post‐cardiac arrest syndrome. Clinical practice guidelines on post‐resuscitation cardiac arrest care from international medical organizations outline ...
Christy Cecil Forehand, Scott Thomas Benken, Melanie Madorsky, Adham Mohamed, Jerika V. Nguyễn, Deepali Dixit, Jolie Gallagher, William Anthony Hawkins, Mojdeh Saba Heavner, Emory Johnson, Lauren Lozano, Melanie Sisco, Angela A. Slampak‐Cindric, Susan Elizabeth Smith, Katherine Spezzano, Bayard Angel Taylor II, Nathaniel Brett Wayne, David John Gagnon   +17 more
wiley   +1 more source

The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro [PDF]

Maria Gabriella Matera, Barbara Rinaldi, Cecilia Calabrese, Carmela Belardo, Luigino Calzetta, Mario Cazzola, Clive Page   +6 more
openalex   +1 more source

Involvement of Ca2+ Signaling in the Synergistic Effects between Muscarinic Receptor Antagonists and β2-Adrenoceptor Agonists in Airway Smooth Muscle [PDF]

, 2016
Kentaro Fukunaga, Hiroaki Kume, Tetsuya Oguma, Wataru Shigemori, Yuji Tohda, Emiko Ogawa, Yasutaka Nakano   +6 more
openalex   +1 more source

A Mechanism‐Based Multi‐Level Population PK/PD Model for Potassium‐Competitive Acid Blockers

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
Schematic overview of a mechanism‐based, multi‐level population model for potassium‐competitive acid blockers. ABSTRACT Potassium‐competitive acid blockers (PCABs) are emerging alternatives to proton pump inhibitors for the treatment of acid‐related diseases.
Woojin Jung, Jaeyeon Lee, Hyeseon Jeon, Taewook Sung, Hwi‐yeol Yun, Soyoung Lee, Jung‐woo Chae   +6 more
wiley   +1 more source

Assessment of Affinities and Dissociation Potencies of Several 5-HT2 Antagonists to and from M2 Muscarinic Receptor in Rat Heart Membranes

, 2003
Mamunur Rashid, Habib Abul Muntasir, Masatomo Watanabe, Mikio Nakazawa, Masanori Ozaki, Takafumi Nagatomo   +5 more
openalex   +2 more sources

Long‐acting muscarinic antagonist + long‐acting beta agonist versus long‐acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta‐analysis [PDF]

, 2015
Nobuyuki Horita, Naoki Miyazawa, Koji Tomaru, Miyo Inoue, Takeshi Kaneko   +4 more
openalex   +1 more source

Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units
Roela Sadushi‐Koliçi, Leila Alajbegovic, Vladimir Gojic, Nika Skoro‐Sajer, Ioana Campean, Inbal Shafran, Deddo Mörtl, Christian Gerges, Irene M. Lang   +8 more
wiley   +1 more source

Evening administration of long-acting muscarinic antagonists in COPD - a randomized controlled trial. [PDF]

BMC Pulm Med
Sivapalan P, Rømer V, Jordan A, Johansen ND, Pareek M, Modin D, Mathioudakis AG, Vestbo J, Vognsen AK, Eklöf J, Hurst JR, Klausen TW, Biering-Sørensen T, Jensen JS.   +13 more
europepmc   +1 more source

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials

, 2019
James F. Donohue, Gregory Feldman, Sanjay Sethi, Chris N. Barnes, Srikanth Pendyala, David L. Bourdet, Glenn Crater   +6 more
openalex   +1 more source